AngioDynamics (NASDAQ:ANGO) Issues FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY25 earnings guidance on Thursday morning. The company provided EPS guidance of ($0.42)-($0.38) for the period, compared to the consensus EPS estimate of ($0.41). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $284.37 million. AngioDynamics also updated its FY 2025 guidance to -0.420–0.380 EPS.

Analyst Ratings Changes

A number of equities research analysts have commented on ANGO shares. HC Wainwright reissued a buy rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Friday. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a buy rating for the company in a research note on Friday.

AngioDynamics Stock Performance

ANGO stock opened at $6.10 on Friday. The business has a 50-day simple moving average of $7.48 and a two-hundred day simple moving average of $6.63. The company has a market capitalization of $244.34 million, a P/E ratio of -1.26 and a beta of 0.65. AngioDynamics has a 52-week low of $5.26 and a 52-week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. The business had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. AngioDynamics’s revenue was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) earnings per share. As a group, sell-side analysts forecast that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.